Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer
Cancer Network,
Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the…
Metastatic colorectal cancer (mCRC) is the second most common cause of cancer-related death worldwide.1 In the mid-1980s, the…
INDIANAPOLIS, Sept. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S.
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…
ERBITUX® is the first and only anti-EGFR antibody approved, in combination with encorafenib, specifically for adults with…